- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07950982
STIL Block Versus Paravertebral Block for Pain Relief After Modified Radical Mastectomy (STIL-PVB-MRM)
Ultrasound-Guided Subtransverse Interligamentary (STIL) Block Versus Paravertebral Block (PVB) for Postoperative Analgesia in Modified Radical Mastectomy: A Randomized Controlled Trial
Breast cancer surgery, particularly modified radical mastectomy (MRM), can cause significant postoperative pain. Effective pain management is important to improve patient comfort, facilitate recovery, reduce opioid consumption, and potentially decrease the risk of persistent post-mastectomy pain.
This randomized controlled clinical trial aims to compare the effectiveness of ultrasound-guided subtransverse interligamentary (STIL) block and thoracic paravertebral block (PVB) for postoperative pain relief in female patients undergoing modified radical mastectomy.
Eligible patients will be randomly allocated into three groups: the STIL block group, the PVB group, and a control group receiving general anesthesia without a regional block. Both regional blocks will be performed under ultrasound guidance at the T4 thoracic level using 25 mL of 0.25% bupivacaine combined with 4 mg dexamethasone.
Postoperative pain will be assessed using a visual analogue scale (VAS) at rest and during movement. The study will also evaluate postoperative morphine consumption, time to first rescue analgesia, intraoperative fentanyl requirements, recovery characteristics, patient satisfaction, postoperative nausea and vomiting, and block-related complications.
The primary objective is to compare postoperative pain scores at rest 24 hours after surgery between patients receiving STIL block and those receiving PVB.
The findings may help determine whether STIL block provides an effective alternative to thoracic paravertebral block for postoperative analgesia following modified radical mastectomy.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
BACKGROUND AND RATIONALE:
Modified radical mastectomy (MRM) is a commonly performed surgical procedure for the management of breast cancer. Postoperative pain remains an important concern and may interfere with respiratory function, delay mobilization, prolong hospital stay, and negatively affect patient recovery and satisfaction.
Thoracic paravertebral block (PVB) is an established regional anesthesia technique for breast surgery that provides effective postoperative analgesia and reduces opioid requirements. However, it requires considerable technical expertise and carries potential complications, including pleural puncture, pneumothorax, vascular injury, and inadvertent neuraxial spread of local anesthetic.
The ultrasound-guided subtransverse interligamentary (STIL) block is a relatively novel paraspinal regional anesthesia technique. Local anesthetic is injected into the space between the transverse process and the intertransverse ligament, allowing spread toward the thoracic paravertebral space.
This study aims to compare the postoperative analgesic efficacy of STIL block with thoracic PVB in patients undergoing MRM.
STUDY DESIGN AND POPULATION:
This is a prospective, randomized, controlled clinical trial involving 60 female patients with breast cancer scheduled for modified radical mastectomy at the National Cancer Institute, Cairo University.
Eligible patients will be aged 18-65 years, have an ASA physical status of II-III, and a body mass index between 20 and 35 kg/m².
Patients will be randomly allocated into three equal groups, with 20 patients in each group:
Group I - STIL Block:
Patients will receive ultrasound-guided subtransverse interligamentary block at the T4 thoracic level before induction of general anesthesia.
Group II - Paravertebral Block:
Patients will receive ultrasound-guided thoracic paravertebral block at the T4 thoracic level before induction of general anesthesia.
Group III - Control:
Patients will receive general anesthesia without any regional nerve block.
INTERVENTION DETAILS:
Both regional anesthesia techniques will be performed approximately 30 minutes before induction of general anesthesia.
In the STIL group, a 22-gauge echogenic spinal needle will be advanced under ultrasound guidance into the subtransverse interligamentary space at T4. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.
In the PVB group, a 22-gauge echogenic spinal needle will be advanced under ultrasound guidance into the thoracic paravertebral space at T4. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.
All patients will receive standardized general anesthesia and multimodal postoperative analgesia according to the study protocol.
GENERAL ANESTHESIA AND POSTOPERATIVE ANALGESIA:
General anesthesia will be induced using intravenous propofol, fentanyl, and rocuronium and maintained with sevoflurane in oxygen-enriched air.
All patients will receive intravenous paracetamol 1 g and ketorolac 30 mg as part of the multimodal analgesic regimen, subject to suitability.
Postoperative analgesia will include intravenous paracetamol 1 g and ketorolac 30 mg every 8 hours. Rescue analgesia will be provided using intravenous morphine 3 mg increments whenever the visual analogue scale (VAS) pain score is ≥4.
OUTCOME ASSESSMENT:
Primary Outcome:
The primary outcome is the postoperative pain score at rest, assessed using the visual analogue scale (VAS) 24 hours after surgery, comparing the STIL and PVB groups.
Secondary Outcomes:
- Postoperative pain scores at rest and during movement at predefined time points.
- Total postoperative morphine consumption during the first 24 hours.
- Time to first rescue analgesic request.
- Total intraoperative fentanyl consumption.
- Hemodynamic parameters, including heart rate and mean arterial pressure.
- Dermatomal sensory distribution and block failure rate.
- Block performance time, number of needle passes, and number of attempts.
- Postoperative nausea and vomiting.
- Patient satisfaction with postoperative analgesia.
- Recovery characteristics.
- Block-related complications and adverse events.
BLINDING AND RANDOMIZATION:
Patients will be randomly allocated using a computer-generated randomization sequence and sequentially numbered opaque sealed envelopes.
The study will be double-blinded. Patients and postoperative outcome assessors will be unaware of group allocation. Regional blocks will be performed by an anesthesiologist who will not participate in postoperative data collection. Identical adhesive dressings will be applied to the thoracic area in all patients.
STATISTICAL ANALYSIS:
Data will be analyzed using IBM SPSS Statistics version 27. Appropriate parametric and nonparametric statistical tests will be used according to data distribution. A p-value ≤0.05 will be considered statistically significant.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Armia M shafeek, MD
- Numéro de téléphone: 01200456797
- E-mail: Armia.shafeek@nci.cu.edu.eg
Lieux d'étude
-
-
-
Cairo, Egypte, 11796
- Recrutement
- National Cancer Institute, Cairo University
-
Contact:
- Armia M shafeek, MD
- Numéro de téléphone: +201200456797
- E-mail: Armia.shafeek@nci.cu.edu.eg
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
**Inclusion Criteria:**
- Female patients scheduled for modified radical mastectomy for breast cancer.
- American Society of Anesthesiologists (ASA) physical status II-III.
- Age between 18 and 65 years.
- Body mass index (BMI) between 20 and 35 kg/m².
**Exclusion Criteria:**
- Patient refusal to participate.
- ASA physical status IV or higher.
- Age below 18 or above 65 years.
- BMI below 20 or above 35 kg/m².
- Known allergy to local anesthetics, opioids, or any of the study medications.
- History of chronic pain or psychiatric illness.
- Contraindications to regional anesthesia, including local infection at the injection site, coagulopathy, or pre-existing neuropathy.
- Severe cardiac, hepatic, renal, or respiratory disease.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: STIL Block Group
Patients will receive ultrasound-guided Subtransverse Interligamentary (STIL) block at the T4 thoracic level, performed approximately 30 minutes before induction of general anesthesia. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally. |
Ultrasound-guided Subtransverse Interligamentary (STIL) block performed at the T4 thoracic level approximately 30 minutes before induction of general anesthesia. A 22-gauge echogenic spinal needle will be advanced in-plane beneath the intertransverse ligament into the subtransverse interligamentary space. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally. |
|
Comparateur actif: Paravertebral Block Group
Patients will receive ultrasound-guided thoracic Paravertebral Block (PVB) at the T4 thoracic level, performed approximately 30 minutes before induction of general anesthesia. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally. |
Ultrasound-guided thoracic paravertebral block performed at the T4 thoracic level approximately 30 minutes before induction of general anesthesia. A 22-gauge echogenic spinal needle will be advanced in-plane toward the thoracic paravertebral space. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally. |
|
Aucune intervention: Control Group
Patients will receive general anesthesia without any regional anesthesia block. Intraoperative and postoperative analgesia will be provided according to the standardized multimodal analgesic protocol, including intravenous paracetamol and ketorolac, with intravenous morphine as rescue analgesia when the VAS pain score is ≥4. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Postoperative Pain Score at Rest at 24 Hours
Délai: 24 hours after surgery
|
Postoperative pain intensity at rest will be assessed using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain), 24 hours after surgery. The primary comparison will be between the STIL block and paravertebral block groups. |
24 hours after surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Postoperative Pain Scores at Rest and During Movement
Délai: PACU, 1, 2, 4, 6, 12, and 18 hours after surgery
|
Pain intensity will be assessed using the Visual Analogue Scale (VAS), ranging from 0 to 10, both at rest and during movement. |
PACU, 1, 2, 4, 6, 12, and 18 hours after surgery
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Armia M shafeek, MD, National Cancer Institute, Cairo
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- La douleur
- Manifestations neurologiques
- Complications postopératoires
- Processus pathologiques
- Tumeurs par site
- Tumeurs
- Maladies de la peau
- Maladies du sein
- Conditions pathologiques, signes et symptômes
- Maladies de la peau et du tissu conjonctif
- Signes et symptômes
- Douleur, Postopératoire
- Tumeurs mammaires
- Système digestif et phénomènes physiologiques oraux
- Dentisterie
- Phénomènes physiologiques dentaires
- Occlusion dentaire
Autres numéros d'identification d'étude
- AP2611-201-253-215
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Individual participant data will not be shared with other researchers because no data-sharing plan has been established for this study. Study results will be disseminated through scientific publications, while participant confidentiality and data privacy will be maintained in accordance with institutional ethical requirements.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .